You searched for: ivacaftor

9 results

Commissioning statement: Ivacaftor, tezacaftor/ivacaftor, lumacaftor/ivacaftor and elexacaftor/tezacaftor/ivacaftor for cystic fibrosis

NHS England has confirmed that ivacaftor, tezacaftor/ivacaftor and elexacaftor/tezacaftor/ivacaftor will be made available as treatment options for people with cystic fibrosis who have one of an expanded range of cystic fibrosis transmembrane conductance regulator (CFTR) mutations within the criteria set out in this commissioning statement.

First young children now taking life-changing cystic fibrosis treatment on NHS

One of the first children to receive the game-changing cystic fibrosis treatment, Kaftrio, on the NHS has told how she felt better within hours. Seven-year-old Kate Farrer started taking revolutionary drug on Sunday, and her family say she started to feel an improvement just three hours later. The little girl from London is one of […]

‘Miracle’ Cystic Fibrosis treatment for children on the NHS

Hundreds of children are set to benefit from a ‘miracle’ treatment for cystic fibrosis, which has already changed the lives of thousands of people, the NHS has announced today. Patients here were some of the first in Europe to benefit from Kaftrio when NHS England secured a landmark deal in June 2020. Nine out of […]

NHS patients among first in Europe to benefit from landmark deal for cystic fibrosis treatment

NHS patients in England will be some of the first people in Europe to benefit from a new “truly life-transforming” treatment for cystic fibrosis, health service chief executive Sir Simon Stevens has announced today. Three in five patients with the deadly genetic condition could benefit from the ‘triple combination’ treatment produced by Vertex Pharmaceuticals. This […]

Policy statements

In circumstances when NHS England needs to implement a commissioning policy quickly, a policy statement or urgent policy statement will be developed. These policy statements have been through the standard development process for all policies, including evidence review, impact analysis and decision by the Clinical Priorities Advisory Group (CPAG), however they have not been subject […]

Harnessing technology and innovation

The major work programmes mapped out in this Plan are underpinned by an agreed, costed and phased NHS technology plan, building on the recommendations of the Wachter review. It will simplify patient access to care, in the most appropriate location, while supporting people in managing their own health. Specifically, during the coming two years we […]

NHS England announces major extension of national HIV prevention programme with Public Health England and funding for ten new specialised treatments

NHS England will fund a major extension to the national HIV prevention programme led by Public Health England with the aim of supporting those most at risk and reducing the incidence of HIV infection. It has also decided to routinely commission ten new specialised treatments as part of the annual prioritisation process for specialised treatments. […]

NHS England announces provisional investment decisions for specialised services

NHS England has today (11 July) set out the results of its annual process for deciding which new treatments and services it will make available to patients. Around a hundred policies were considered over the course of the year. Many of these were considered as ‘In Year Service Developments’ – policies which are cost-saving or […]

NHS England announces annual investment decisions for certain specialised services

NHS England has today (2 July) set out its planned investment decisions for certain specialised services as part of its annual commissioning round. The decision follows a three-month public consultation on the principles and processes NHS England will follow when making investment decisions. Feedback from the consultation has helped inform the way these decisions have […]